PortfoliosLab logo
Exelixis, Inc. (EXEL)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US30161Q1040

CUSIP

30161Q104

IPO Date

Apr 7, 2000

Highlights

Market Cap

$10.06B

EPS (TTM)

$1.76

PE Ratio

20.55

PEG Ratio

2.27

Total Revenue (TTM)

$1.74B

Gross Profit (TTM)

$1.69B

EBITDA (TTM)

$650.08M

Year Range

$20.14 - $40.26

Target Price

$38.05

Short %

9.04%

Short Ratio

6.64

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

Exelixis, Inc. (EXEL) returned 8.62% year-to-date (YTD) and 69.26% over the past 12 months. Over the past 10 years, EXEL delivered an annualized return of 25.86%, outperforming the S&P 500 benchmark at 10.46%.


EXEL

YTD

8.62%

1M

4.96%

6M

-0.22%

1Y

69.26%

5Y*

5.71%

10Y*

25.86%

^GSPC (Benchmark)

YTD

-3.77%

1M

7.44%

6M

-5.60%

1Y

8.37%

5Y*

14.12%

10Y*

10.46%

*Annualized

Monthly Returns

The table below presents the monthly returns of EXEL, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-0.45%16.71%-4.57%6.04%-7.61%8.62%
2024-9.30%0.64%8.36%-1.14%-7.54%3.60%4.36%11.00%-0.31%27.94%9.82%-8.67%38.81%
20239.85%-3.06%13.64%-5.72%5.36%-0.88%3.14%13.60%-2.41%-5.77%5.93%10.00%49.56%
2022-0.98%13.43%10.42%-1.46%-17.95%13.58%0.48%-15.20%-11.61%5.74%3.02%-6.09%-12.25%
202110.66%-2.48%4.29%8.99%-8.41%-19.20%-7.52%13.77%10.28%1.75%-21.94%8.87%-8.92%
2020-2.38%8.08%-7.37%43.41%0.06%-3.93%-2.74%-3.77%10.04%-16.24%-6.45%4.75%13.90%
201919.83%-5.01%6.30%-17.39%-0.36%9.09%-0.47%-6.68%-10.91%-12.64%7.64%5.95%-10.42%
2018-0.30%-14.88%-14.15%-6.00%-0.43%3.81%-3.81%-9.23%-5.69%-21.73%46.43%-3.15%-35.30%
201721.53%18.82%0.65%3.37%-16.47%31.64%10.07%7.86%-17.13%2.31%9.24%12.26%103.89%
2016-18.09%-21.21%9.89%15.25%40.78%20.34%17.54%21.46%14.71%-17.20%59.77%-11.88%164.36%
201529.86%56.68%-12.29%0.00%22.57%19.37%52.39%3.84%-5.71%7.31%-4.98%-1.40%291.67%
201412.23%2.62%-49.86%0.00%-6.50%2.42%18.88%2.73%-63.04%11.11%-2.35%-13.25%-76.51%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 92, EXEL is among the top 8% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of EXEL is 9292
Overall Rank
The Sharpe Ratio Rank of EXEL is 9595
Sharpe Ratio Rank
The Sortino Ratio Rank of EXEL is 9292
Sortino Ratio Rank
The Omega Ratio Rank of EXEL is 9292
Omega Ratio Rank
The Calmar Ratio Rank of EXEL is 8585
Calmar Ratio Rank
The Martin Ratio Rank of EXEL is 9696
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Exelixis, Inc. (EXEL) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Exelixis, Inc. Sharpe ratios as of May 11, 2025 (values are recalculated daily):

  • 1-Year: 1.91
  • 5-Year: 0.19
  • 10-Year: 0.52
  • All Time: 0.05

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Exelixis, Inc. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


Exelixis, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Exelixis, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Exelixis, Inc. was 97.38%, occurring on Dec 24, 2014. The portfolio has not yet recovered.

The current Exelixis, Inc. drawdown is 26.56%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-97.38%Jul 27, 20003626Dec 24, 2014
-38.22%May 8, 200012May 23, 20008Jun 5, 200020
-9.04%Jun 23, 20002Jun 26, 20002Jun 28, 20004
-8.99%Jul 13, 20002Jul 14, 20006Jul 24, 20008
-8.48%Jun 8, 20007Jun 16, 20003Jun 21, 200010

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Exelixis, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Exelixis, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -100.0%.


-0.200.000.200.400.600.80202120222023202420250
0.47
Actual
Estimate

Valuation

The Valuation section provides an overview of how Exelixis, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for EXEL, comparing it with other companies in the Biotechnology industry. Currently, EXEL has a P/E ratio of 20.6. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for EXEL compared to other companies in the Biotechnology industry. EXEL currently has a PEG ratio of 2.3. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for EXEL relative to other companies in the Biotechnology industry. Currently, EXEL has a P/S ratio of 4.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for EXEL in comparison with other companies in the Biotechnology industry. Currently, EXEL has a P/B value of 4.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items